Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data.
about
Resource Effective Strategies to Prevent and Treat Cardiovascular DiseaseDrugs for cardiovascular disease in India: perspectives of pharmaceutical executives and government officials on access and development-a qualitative analysisPhone-based Intervention under Nurse Guidance after Stroke (PINGS): study protocol for a randomized controlled trialStroke Prevention in Atrial Fibrillation: Focus on Latin AmericaGlobal Shifts in Cardiovascular Disease, the Epidemiologic Transition, and Other Contributing Factors: Toward a New Practice of Global Health CardiologyHeart Disease and Stroke Statistics-2017 Update: A Report From the American Heart AssociationPrevention of stroke: a strategic global imperative.Setting priorities to address cardiovascular diseases through universal health coverage in low- and middle-income countriesWealth and cardiovascular health: a cross-sectional study of wealth-related inequalities in the awareness, treatment and control of hypertension in high-, middle- and low-income countriesStrengths and Limitations of Using the Polypill in Cardiovascular Prevention.Prevalence of cardiovascular medication on secondary prevention after myocardial infarction in China between 1995-2015: A systematic review and meta-analysisAccess to Medications for Cardiovascular Diseases in Low- and Middle-Income CountriesThe Cardio-PadTM project: progress and remaining challengesEducational intervention to improve effectiveness in treatment and control of patients with high cardiovascular risk in low-resource settings in Argentina: study protocol of a cluster randomised controlled trial.Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks.Availability, Price, and Affordability of Selected Essential Medicines for Chronic Diseases in 11 Countries of the Asia Pacific Region: A Secondary Analysis.Integrating cardiovascular diseases, hypertension, and diabetes with HIV services: a systematic review.Comprehensive efforts to increase adherence to statin therapy.Association of Household Wealth Index, Educational Status, and Social Capital with Hypertension Awareness, Treatment, and Control in South Asia.Vulnerabilities to Health Disparities and Statin Use in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study.Progress in Medicine: Experts Take Stock.Baseline Prescription and One-Year Persistence of Secondary Prevention Drugs after an index Stroke in Central Ghana.Availability of anticancer medicines in public and private sectors, and their affordability by low, middle and high-income class patients in Pakistan.An enquiry based on a standardised questionnaire into knowledge, awareness and preferences concerning the care of familial hypercholesterolaemia among primary care physicians in the Asia-Pacific region: the "Ten Countries Study".Does greater individual social capital improve the management of hypertension? Cross-national analysis of 61 229 individuals in 21 countries.Availability, Sales, and Affordability of Tobacco Cessation Medicines in Kerala, India.Socioeconomic Status and Cardiovascular Disease: an Update.Fixed-dose combination therapy to reduce the growing burden of cardiovascular disease in low- and middle-income countries: feasibility and challenges.Inequalities in the use of secondary prevention of cardiovascular disease by socioeconomic status: evidence from the PURE observational study.Comparative health system performance in six middle-income countries: cross-sectional analysis using World Health Organization study of global ageing and health.Health inequalities in secondary prevention.Burden of cardiovascular diseases in the Eastern Mediterranean Region, 1990-2015: findings from the Global Burden of Disease 2015 study.The Availability and Affordability of Cardiovascular Medicines for Secondary Prevention in Tehran Province (Iran).Quantifying the financial burden of households' out-of-pocket payments on medicines in India: a repeated cross-sectional analysis of National Sample Survey data, 1994-2014.Availability and affordability of biologic versus non-biologic anticancer medicines: a cross-sectional study in Punjab, Pakistan.Polypill: an affordable strategy for cardiovascular disease prevention in low-medium-income countries.Equity in access to non-communicable disease medicines: a cross-sectional study in Kenya.Heart Failure in Sub-Saharan AfricaHigh Blood Pressure 2016: Why Prevention and Control Are Urgent and Important. The World Hypertension League, International Society of Hypertension, World Stroke Organization, International Diabetes Foundation, International Council of CardiovascularThe economic burden of cardiovascular disease and hypertension in low- and middle-income countries: a systematic review
P2860
Q26768304-44154EF4-1AB9-4721-A097-1703A5400273Q27316535-52CC8AF7-96D4-4919-83A4-B98ECD96D52FQ27331952-F5D18E7F-63CA-4984-AB18-35C611C020D1Q28359631-0D8D071A-10DF-4CE4-93B4-C0ECDDF3CE3FQ28395689-C6C72CF5-CCFD-4DA1-BAF2-179BA227AF5CQ30238784-8FB362B4-F541-4586-9D39-ABA9670BF2ABQ30248840-F194B8BC-8AE6-4AFA-A0C5-DC281F0C4D41Q30378137-10E922DF-6311-41DB-9CD9-979F92163E45Q30379976-981C1DF5-31E0-4269-935F-AB254825BE43Q33581084-94647BAE-795C-452D-9963-304BC81C0D15Q33584809-5A42C499-328D-4E31-BA7A-F090345E972FQ36936076-1FB96A7A-71BC-4A59-BBA3-CC0ED4B247F1Q37598040-0953C3FF-4E97-4313-90D3-6E830AD23A5FQ37627267-FFD9FCFE-7DC9-456F-85E8-A9E4DF91B456Q38641699-E6432334-E261-4DD1-BA81-DA407C844CDEQ38843019-47899E22-FE69-4DA0-9C27-96BEDFFE644DQ39041873-CC0D09B8-85C6-4A91-9FAC-CBF6D9FF44A5Q39080414-F7561429-60BD-4698-8C9D-B279DFA402D4Q40376891-1829EC50-CBAB-4290-8AB6-9D3FE1F155E0Q42373669-F5992206-BCC2-4D62-B1AB-834F6193B2E6Q43112618-C2B7583F-DE98-4EA5-9689-975B8A6EB569Q46576530-6278AEA1-0413-43C6-BCAA-8941C4257285Q47097742-B427BEB3-8784-40C4-9FA8-8DD514AE920BQ47161967-E7E2F1CF-A9A3-4D65-BDEA-5B9723FAA484Q47404727-DD621090-6F06-473C-851E-90AA51073648Q47576469-108DE74C-DFDA-4694-9E57-2A48510EA08DQ47671507-EC0A225C-3654-422C-B361-7F354EF5D598Q47874524-46FCF0FE-5216-4D40-BE55-23CCC8E93489Q50057438-DBB8B492-A8B2-48AB-A82C-61BA7DA56E0CQ50427555-73F9DFF2-1A72-4B88-B82B-4F1C5C662D11Q52838035-94C6BD16-EC7B-4CA2-A5C9-99ED426CE003Q53692480-BC0CB945-0F20-46B9-BFE6-09B6D78E9975Q54985557-80E53B9B-9A36-4254-BBF1-C92B1AA71F25Q55234156-350472D6-DD72-4444-BABC-95F76946C385Q55279429-FF205EFD-8EDB-48D9-A72A-E1137D9B72DFQ55434208-AF81DFC1-D887-42B9-BB57-FDAC38DFA860Q55510606-3D706D7A-FD9F-458D-A064-384754A393B2Q56381156-CE2F1EB1-E33E-4D40-872D-A5544CDC9F0DQ57252706-DDA25FB5-1DFB-4690-8112-2A34BC69BCBFQ58798921-4CFFB123-EBA6-48CC-8AFF-3FDF848B46CC
P2860
Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data.
description
2015 nî lūn-bûn
@nan
2015 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Availability and affordability ...... alysis of the PURE study data.
@ast
Availability and affordability ...... alysis of the PURE study data.
@en
type
label
Availability and affordability ...... alysis of the PURE study data.
@ast
Availability and affordability ...... alysis of the PURE study data.
@en
prefLabel
Availability and affordability ...... alysis of the PURE study data.
@ast
Availability and affordability ...... alysis of the PURE study data.
@en
P2093
P50
P1433
P1476
Availability and affordability ...... alysis of the PURE study data.
@en
P2093
Ahmet Temizhan
Alvaro Avezum
Amiram Gafni
Annamarie Kruger
Clara Chow
Fernando Lanas
Harry Shannon
Khalid Yusoff
Khawar Kazmi
Krishnapillai Vijayakumar
P356
10.1016/S0140-6736(15)00469-9
P407
P50
P577
2015-10-20T00:00:00Z